Consistent with the reported disparities in mutational burden, a higher response rate of anti-PD-1 therapy in PD-L1-positive tumors is observed in TNBC than in ER+ breast cancer (18.5% vs. 12%) [38]. The gene discussed is CD274; the disease is breast carcinoma.